After administration of tocilizumab, the CT scan showed improvement in the patient's lungs, specifically due to a reduction in ground glass opacities. 

Johns Hopkins University

This case report was conducted on a 65 year old man with stage IV lung adenocarcinoma being treated with chemo-immunotherapy who developed COVID-19 pneumonia.  The patient was hospitalized and received therapy and additional oxygen support, but his clinical conditions did not get better.  However, upon administering two doses of tocilizumab to the patient, an immediate improvement in clinical conditions was observed.  The patient's level of C reactive protein decreased significantly from 212 mg/dl to 37 mg/dl, his ratio of arterial oxygen partial pressure to fractional inspired oxygen improved, and additional required oxygen supplementation decreased gradually.  There were no acute side effects that occurred.  The patient was eventually discharged.
 

Case Report of Tocilizumab for COVID-19 Pneumonia in a Non Small Cell Lung Cancer Patient Treated with Chemo-Immunotherapy

Bonomi, M., Maltese, M., Brighenti, M., Muri, M., &amp; Passalacqua, R. (2020). Tocilizumab for COVID-19 pneumonia in a non small cell lung cancer patient treated with chemo-immunotherapy. Clinical Lung Cancer. doi:10.1016/j.cllc.2020.08.002

Learn Before

Related